Senior Director, Clinical Pharmacology Group Lead; Global Product Development
Pfizer
Audubon, Pennsylvania
Donna S. Cox is a Senior Director, Group Lead in Clinical Pharmacology within Global Product Development at Pfizer and received her MS from the Johns Hopkins University, PhD from University of Maryland in Pharmaceutical Sciences and completed post-doctoral training at Walter Read Army Institute of Research (WRAIR) Clinical Pharmacology Fellowship Program. She has over 20 years of experience as a clinical pharmacologist in the pharmaceutical industry where she has worked in several therapeutic areas such as CV, Inflammation, CNS, Respiratory, OAB, Rare Disease and Antivirals. Donna has over thirty published peer reviewed articles and abstracts. She has authored and critiqued numerous reports prior to their submission to regulatory agencies (i.e., NDAs such as Mekinist and Austedo, MAAs and PMDAs), such as 7.2.2, and 7.2.1. In Pfizer, Donna has acted as the clinical pharmacology group lead for biosimilars (adalimumab, infliximab, rituximab etc.). Recently, she was the clinical pharmacology lead on Paxlovid, which received EUA approval in December 2021 for the treatment in adults and children who have had a positive SARS-CoV-2 viral test and are at high risk for progression to sever COVID-19, including hospitalization or death.
Disclosure information not submitted.
Monday, October 17, 2022
3:15 PM – 3:30 PM ET